[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Roivant Sciences insider sale and post-transaction holding. The company's CFO and director, Richard Pulik, reported a disposition of 2,129 common shares on 09/20/2025 at a price of $15.04 per share. The filing states this disposition represents a "net settlement" to satisfy tax withholding related to previously granted RSUs. After the transaction Pulik beneficially owns 391,849 shares.

Positive

• Reporting person retains a substantial stake of 391,849 shares, indicating continued ownership interest
• Disposition is described as a net settlement for tax withholding on RSUs, which is a routine, non-sale-based transfer

Negative

• 2,129 shares were disposed of at $15.04 per share, reducing the reporting person's holdings
• Filing provides no additional context on the original RSU grant dates or amounts, limiting deeper assessment

Insights

Financial Analyst

TL;DR: Routine RSU tax-withholding sale; holding remains substantial.

The Form 4 shows a small, routine disposition of 2,129 shares through net settlement of vested RSUs to cover tax obligations, not an open-market sale. The transaction price reported is $15.04 per share and leaves the reporting person with 391,849 shares, indicating ongoing significant insider ownership. For investors, this is informational rather than a signal of changing conviction.

Corporate Governance Expert

TL;DR: Governance disclosure consistent with Section 16 requirements; no governance red flags.

The filing is a standard Section 16 disclosure: it identifies the reporting person as CFO and director and discloses the RSU net-settlement explaining the nature of the disposition. The signature is by an attorney-in-fact and the dates are provided. There are no indications of unusual timing or multiple related transactions in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pulik Richard

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
09/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/20/2025		F		2,129(1)	D	$15.04	391,849	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

	By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Richard Pulik report on Form 4 for ROIV?

The Form 4 reports a disposition of 2,129 common shares on 09/20/2025 at $15.04 per share.

Why were the shares disposed of according to the filing?

The filing states the disposition represents net settlement to satisfy tax withholding obligations related to vested RSUs.

How many ROIV shares does Richard Pulik own after this transaction?

After the reported transaction, Richard Pulik beneficially owns 391,849 shares.

What is Richard Pulik's role at Roivant Sciences as listed on the Form 4?

The Form 4 identifies Richard Pulik as a Director and the company's CFO (Officer).

When was the Form 4 signed and by whom?

The form is signed by Jo Chen as Attorney-in-Fact for Richard Pulik on 09/23/2025.